Skip to content
vigabatrin.org

Vigabatrin research in plain language

On this page

Short answer: the most important vigabatrin studies show that it works well for infantile spasms caused by tuberous sclerosis, less well than hormones for most other infantile spasms, and that it carries a real risk of vision loss. Preventive use in tuberous sclerosis is still debated, because the two trials of it disagree.1,2,3,4

Each summary below covers what the study asked, who was in it, what it found, and its limits. These results shape how vigabatrin is used for infantile spasms and for tuberous sclerosis, and how vision loss is monitored. Short answers to common questions are on the vigabatrin FAQ, and the full reference list is on sources.

Ready-to-use liquid vs powder study (2025)

What it asked. Can caregivers measure a dose more accurately from the ready-to-use liquid than from powder they mix themselves?5

Who. 30 lay users: 15 caregivers who had given vigabatrin powder before and 15 people who had never used an oral syringe. Each prepared one 1,125 mg dose of each product, using only written instructions.5

What it found.

  • All 30 ready-to-use doses were within 5% of the target. Only 23 of 30 powder doses (77%) were within 10%.
  • Powder doses ranged from 425 mg to 1,390 mg, from 62% too low to 24% too high.
  • On average, the liquid delivered 99% of the target dose and the powder 90%.
  • People measured volumes equally well with both, so the authors attribute the errors to mixing the powder.
  • Experienced caregivers were no better with powder (10 of 15 within 10%) than first-time users (13 of 15).5

Limits. The authors were employees of the company that makes the ready-to-use liquid. The study was small, each person made a single dose in a test setting, and the liquid used was a stand-in solution whose dose was calculated from volume rather than measured in the lab. People could not ask questions, which the authors note is not how the label expects caregivers to be taught. The 1,125 mg target was larger than a typical infant dose. No study has compared seizure outcomes between the two forms.5

Read the paper: Comparison of a ready-to-use vigabatrin solution to reconstituted solutions of vigabatrin powder (open-access PDF, CC BY-NC).

Powder stability study (2025)

What it asked. Does vigabatrin powder stay stable after mixing in water, juice, milk or infant formula?6

What it found. Powder (Vigadrone) mixed in water, apple juice, whole milk or infant formula and kept in the fridge in capped glass met quality standards for strength and impurities at 0, 24 and 48 hours.6

Limits. This was a lab study, not a study of families, and its authors came from the company that makes the powder. The approved labels have not changed: they still say to mix each dose in water, use it right away and throw away the rest.6,7

PREVeNT trial (2023)

What it asked. If infants with tuberous sclerosis complex (TSC) start vigabatrin early, before seizures, does it improve development and prevent epilepsy?4

Who. 56 infants with TSC, randomly assigned to vigabatrin (29) or placebo (27).4

What it found.

  • Cognitive scores at 24 months were similar in both groups.
  • There was no difference in how many children developed epilepsy or drug-resistant epilepsy.
  • Infantile spasms were less common, and started later, with vigabatrin.4

Limits. The trial was small. Its primary outcome, the Bayley-III cognitive score at 24 months, showed no benefit, and it did not show fewer focal seizures. Its results differ from EPISTOP's, below.4

Read the paper: Early treatment with vigabatrin does not decrease focal seizures or improve cognition in tuberous sclerosis complex (open-access PDF, CC BY-NC).

EPISTOP trial (2021)

What it asked. In infants with TSC, does preventive vigabatrin, given before seizures, work better than conventional treatment started after seizures?3

Who. 94 infants with TSC, in a randomized part and an open-label part.3

What it found.

  • The first seizure came later with preventive treatment: after 364 vs 124 days in the randomized part, and 426 vs 106 days in the open-label part.
  • At 24 months, preventive treatment lowered the risk of clinical seizures (odds ratio 0.21) and drug-resistant epilepsy (odds ratio 0.23).
  • No infant on preventive treatment developed infantile spasms (p under 0.001).3

Limits. The trial was small, and part of it was open-label, meaning families and doctors knew which treatment was given. A later trial, PREVeNT, did not find benefits for development or epilepsy overall.3,4

Read the paper: Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial (open-access PDF, CC BY-NC).

ICISS trial (2017 and 2018)

What it asked. For infantile spasms, does adding vigabatrin to hormonal treatment work better than hormonal treatment alone?8

Who. 377 babies with infantile spasms. Vigabatrin was given at 100 mg/kg/day or more.8

What it found.

  • Spasms stopped between days 14 and 42 in 72% on the combination and 57% on hormones alone.8
  • At 18 months, development scores were the same (73.9 vs 72.7), and so were epilepsy rates (30.0% vs 29.2%).
  • Across both groups, babies whose spasms stopped early had higher development scores (79.1 vs 63.2), and a longer delay to treatment was linked to lower scores.9

Limits. The trial was open-label. The faster early response with the combination did not lead to better development at 18 months.8,9

UKISS trial (2004, 2005 and 2010)

What it asked. For infantile spasms not caused by TSC, does hormonal treatment (prednisolone or tetracosactide) work better than vigabatrin?10

Who. 107 babies; babies with TSC were excluded.10

What it found.

  • At days 13 to 14, spasms had stopped in 73% on hormones and 54% on vigabatrin. Side effects were similar.10
  • By 12 to 14 months, spasm-free rates were the same (75% vs 76%). Overall development scores were similar, but babies with no known cause for their spasms scored higher after hormonal treatment (88.2 vs 78.9).11
  • At 4 years, 77 children were traced. Overall scores were not significantly different, but children with no known cause again scored higher after hormones (96 vs 63).12
  • A further analysis found that each step up in the delay before treatment was linked to a 3.9-point lower development score at 4 years.13

Limits. The trial was modest in size, and only part of the original group could be traced at 4 years.12

Time to remission study (2022)

What it asked. How quickly do babies with new infantile spasms respond to treatment, and does a fast response predict a lasting one?14

Who. 395 babies with new-onset infantile spasms, followed at 23 US centers and treated with ACTH, oral steroids or vigabatrin.14

What it found. 43% went into remission within 2 weeks, and 81% of those did so within the first week. The median time to response was 3 days for vigabatrin, 4 days for ACTH and 3 days for steroids. The authors advise reassessing straight away any baby who has not responded after 1 week.14

Limits. This was a prospective observational cohort from the National Infantile Spasms Consortium, not a randomized trial, so it shows patterns rather than proving cause.14

Vigabatrin vs carbamazepine monotherapy trial (1999)

What it asked. As the only medicine for newly diagnosed epilepsy, does vigabatrin work as well as carbamazepine, an established treatment for focal (partial) seizures?15

Who. 459 people with newly diagnosed, previously untreated partial seizures at 44 European centers. They were randomly assigned, double-blind, to carbamazepine 600 mg a day (230) or vigabatrin 2 g a day (229). Doctors could then adjust the dose.15

What it found.

  • The main outcome, time until people stopped the drug because it failed or caused side effects, did not differ between the groups.
  • Vigabatrin was better tolerated, with fewer withdrawals. Rash was less common (3% vs 10%), but psychiatric symptoms (25% vs 15%) and weight gain (11% vs 5%) were more common.
  • Every efficacy outcome favored carbamazepine. The time to a first seizure after the first 6 weeks was clearly longer on carbamazepine (p=0.0001). The time to 6 months without seizures did not differ significantly.15

What it means. The authors concluded that vigabatrin "cannot therefore be recommended as a first-line drug for monotherapy" in this group.15 Lasting visual field loss linked to vigabatrin had been reported in the BMJ in 1997.16 Today the US label carries a boxed warning for permanent vision loss and says vigabatrin is not a first-line treatment for complex partial seizures; it is used as an add-on when several other medicines have failed.17

Limits. The trial tested vigabatrin only as a first medicine for partial seizures.15 It does not apply to infantile spasms, for which vigabatrin is approved as monotherapy in babies 1 month to 2 years old.17

Vision loss review (2010)

What it asked. How common is visual field loss after vigabatrin?2

Who. 32 studies, with 1,678 people exposed to vigabatrin and 406 controls.2

What it found. Visual field loss was found in 44% of exposed people and 7% of controls. Pooled rates were 52% in adults and 34% in children. Exposed people were about 4 times as likely to have field loss, and risk rose with total dose and with age.2

Limits. Research on children treated as infants has found a range of results: in one small study only 1 of 16 had mild field loss at school age, while a larger international study found defects in 11 of 32.18,19

Brain MRI studies (2017 and 2025)

Some babies on vigabatrin show changes on brain MRI scans. In the data behind the label, they were seen in 22% of babies on vigabatrin vs 4% on other treatments.20,21 In several studies the changes went away after vigabatrin was stopped or over time.22,23 Two studies disagree about what raises the risk.

Hussain 2017. Changes without symptoms were linked to the peak daily dose, not the total dose. Changes with symptoms were seen in 4 of 104 babies and may have been linked to taking hormones at the same time. The authors advise caution above 175 mg/kg/day.24

Sathe 2025. Changes were seen in 17 of 108 babies, 11 with symptoms. Changes with symptoms were linked to taking hormones at the same time, and not to peak dose.25

What this means. Both studies point to combined vigabatrin and hormonal treatment as a possible risk for symptomatic changes. They disagree about whether the dose matters. Both were retrospective studies from a single center (UCLA).24,25

Common questions

What did the PREVeNT trial find?

PREVeNT gave 56 infants with tuberous sclerosis either vigabatrin or placebo before seizures began. Development at 24 months was the same in both groups, and there was no difference in epilepsy or drug-resistant epilepsy. Infantile spasms were less common and started later with vigabatrin.

What did the EPISTOP trial find?

EPISTOP compared preventive vigabatrin with conventional treatment in 94 infants with tuberous sclerosis. Preventive treatment delayed the first seizure and, at 24 months, lowered the risk of clinical seizures, drug-resistant epilepsy and infantile spasms.

Is there a study comparing the ready-to-use liquid with vigabatrin powder?

Yes, one. In a 2025 study of 30 people, every dose measured from the ready-to-use liquid was within 5% of the target, while only 23 of 30 doses mixed from powder were within 10%. The study was small and was run by employees of Pyros, which holds the liquid's FDA application.

How common is vision loss with vigabatrin?

A review of 32 studies found visual field loss in 44% of people exposed to vigabatrin, against 7% of controls. Pooled rates were about 52% in adults and 34% in children, and risk rose with total dose.

What did the vigabatrin vs carbamazepine trial find?

In a double-blind trial of 459 people with newly diagnosed focal (partial) seizures, vigabatrin was better tolerated than carbamazepine but less effective: after the first 6 weeks, the next seizure came sooner on vigabatrin. The authors concluded it could not be recommended as a first medicine, and the US label says it is not a first-line treatment.

References

  1. 1.Xu Z, Gong P, Jiao X, et al. Efficacy of vigabatrin in the treatment of infantile epileptic spasms syndrome: A systematic review and meta-analysis. Epilepsia Open. 2023;8(2):268-277. PMID 36740237 · DOI 10.1002/epi4.12703 PubMedDOI
  2. 2.Maguire MJ, Hemming K, Wild JM, et al. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia. 2010;51(12):2423-2431. PMID 21070215 · DOI 10.1111/j.1528-1167.2010.02772.x PubMedDOI
  3. 3.Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial. Ann Neurol. 2021;89(2):304-314. PMID 33180985 · DOI 10.1002/ana.25956 · NCT02098759 PubMedDOI
  4. 4.Bebin EM, Peters JM, Porter BE, et al. Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial. Ann Neurol. 2024;95(1):15-26 (Epub 2023). PMID 37638552 · DOI 10.1002/ana.26778 · NCT02849457 PubMedDOI
  5. 5.Gibson R, Klima R, Van Horn J. Liquid Medication Dosing Errors: Comparison of a Ready-to-Use Vigabatrin Solution to Reconstituted Solutions of Vigabatrin Powder for Oral Solution. Adv Ther. 2025;42(3):1484-1493. PMID 39899223 · DOI 10.1007/s12325-024-03089-0 · PMC11868180 (Epub Feb 2025; often cited as 2024) PubMedDOI
  6. 6.Zachman M, Gong L, An L, Halvorsen MB. Dissolution and stability of vigabatrin powder in water, fruit juice, milk, and infant formula. Epilepsy Behav Rep. 2025;31:100816. PMID 40838171 · DOI 10.1016/j.ebr.2025.100816 PubMedDOI
  7. 7.VIGADRONE (vigabatrin) for oral solution, revised 12/2025, Upsher-Smith. Source
  8. 8.O'Callaghan FJ, Edwards SW, Alber FD, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 2017;16(1):33-42. PMID 27838190 · DOI 10.1016/S1474-4422(16)30294-030294-0) PubMedDOI
  9. 9.O'Callaghan FJK, Edwards SW, Alber FD, et al. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health. 2018;2(10):715-725. PMID 30236380 · DOI 10.1016/S2352-4642(18)30244-X30244-X) PubMedDOI
  10. 10.Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet. 2004;364(9447):1773-1778. PMID 15541450 · DOI 10.1016/S0140-6736(04)17400-X17400-X) PubMedDOI
  11. 11.Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol. 2005;4(11):712-717. PMID 16239177 · DOI 10.1016/S1474-4422(05)70199-X70199-X) PubMedDOI
  12. 12.Darke K, Edwards SW, Hancock E, et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch Dis Child. 2010;95(5):382-386. PMID 20457702 · DOI 10.1136/adc.2009.160606 PubMedDOI
  13. 13.O'Callaghan FJ, Lux AL, Darke K, et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia. 2011;52(7):1359-1364. PMID 21668442 · DOI 10.1111/j.1528-1167.2011.03127.x PubMedDOI
  14. 14.Yuskaitis CJ, Mytinger JR, Baumer FM, et al. Association of Time to Clinical Remission With Sustained Resolution in Children With New-Onset Infantile Spasms. Neurology. 2022;99(22):e2494-e2503. PMID 36038267 · DOI 10.1212/WNL.0000000000201232 PubMedDOI
  15. 15.Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet. 1999;354(9172):13-19. PMID 10406359 · DOI 10.1016/s0140-6736(98)10531-710531-7) PubMedDOI
  16. 16.Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997;314(7075):180-181. PMID 9022432 · DOI 10.1136/bmj.314.7075.180 PubMedDOI
  17. 17.SABRIL (vigabatrin) tablets prescribing information, revised 10/2021. Source
  18. 18.Gaily E, Jonsson H, Lappi M. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia. 2009;50(2):206-216. PMID 19215279 · DOI 10.1111/j.1528-1167.2008.01961.x PubMedDOI
  19. 19.Riikonen R, Rener-Primec Z, Carmant L, et al. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study. Dev Med Child Neurol. 2015;57(1):60-67. PMID 25145415 · DOI 10.1111/dmcn.12573 PubMedDOI
  20. 20.VIGAFYDE (vigabatrin) oral solution prescribing information, revised 11/2025. Source
  21. 21.Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia. 2009;50(2):195-205. PMID 19054414 · DOI 10.1111/j.1528-1167.2008.01896.x PubMedDOI
  22. 22.Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia. 2009;50(2):184-194. PMID 18783433 · DOI 10.1111/j.1528-1167.2008.01728.x PubMedDOI
  23. 23.Dracopoulos A, Widjaja E, Raybaud C, et al. Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms. Epilepsia. 2010;51(7):1297-1304. PMID 20384718 · DOI 10.1111/j.1528-1167.2010.02564.x PubMedDOI
  24. 24.Hussain SA, Tsao J, Li M, et al. Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent. Epilepsia. 2017;58(4):674-682. PMID 28230253 · DOI 10.1111/epi.13712 PubMedDOI
  25. 25.Sathe R, Shrestha G, Terango A, et al. Symptomatic vigabatrin-associated MRI toxicity is associated with simultaneous hormonal therapy among patients with infantile spasms. Epilepsia Open. 2025;10(1):314-320. PMID 39570186 · DOI 10.1002/epi4.13099 PubMedDOI

All sources used on this site, with summaries